Health Care [ 5/12 ] | Biotechnology [ 24/74 ]
NASDAQ | Common Stock
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.
In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.
The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | -1.37 Decreased by -43.17% | -1.09 Decreased by -26.09% |
| Nov 1, 24 | -0.86 Increased by +20.41% | -0.98 Increased by +12.29% |
| Aug 1, 24 | -0.39 Increased by +60.20% | -1.06 Increased by +63.21% |
| May 2, 24 | -0.20 Increased by +78.26% | -0.71 Increased by +71.83% |
| Feb 22, 24 | -0.96 Decreased by -4.35% | -0.91 Decreased by -5.49% |
| Nov 2, 23 | -1.08 Decreased by -16.13% | -0.82 Decreased by -31.71% |
| Aug 3, 23 | -0.98 Decreased by -1.30 K% | -0.83 Decreased by -18.07% |
| May 4, 23 | -0.92 Increased by +22.69% | -0.83 Decreased by -10.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 5.88 M Increased by +237.08% | -265.05 M Decreased by -57.63% | Decreased by -4.51 K% Increased by +53.24% |
| Sep 30, 24 | 2.73 M Decreased by -33.22% | -162.04 M Increased by +8.45% | Decreased by -5.93 K% Decreased by -37.09% |
| Jun 30, 24 | 2.17 M Increased by +32.11% | -73.46 M Increased by +53.48% | Decreased by -3.39 K% Increased by +64.79% |
| Mar 31, 24 | 211.12 M Increased by +11.46 K% | -35.22 M Increased by +80.09% | Decreased by -16.68% Increased by +99.83% |
| Dec 31, 23 | 1.75 M Decreased by -6.68% | -168.15 M Decreased by -7.81% | Decreased by -9.64 K% Decreased by -15.53% |
| Sep 30, 23 | 4.09 M Increased by +1.11 K% | -177.00 M Decreased by -19.26% | Decreased by -4.33 K% Increased by +90.15% |
| Jun 30, 23 | 1.64 M Decreased by -97.77% | -157.90 M Decreased by -365.98% | Decreased by -9.62 K% Decreased by -12.05 K% |
| Mar 31, 23 | 1.83 M Increased by +7.79% | -176.85 M Increased by +28.32% | Decreased by -9.68 K% Increased by +33.50% |
This website uses cookies. To learn more about cookies, please see our privacy policy .